Moxonidin Actavis (Moxonidine)

Moxonidine selectively stimulates imidazoline I1 receptors in the brainstem. This activation decreases sympathetic outflow, leading to reduced peripheral vascular resistance and a subsequent drop in arterial blood pressure.

The exact dosage of Moxonidin Actavis is determined by the prescribing healthcare professional based on the patient’s condition, response, and any comorbidities. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of moxonidine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, which lowers blood pressure by reducing central sympathetic tone. Unlike ACE inhibitors or beta‑blockers, it does not directly affect the renin‑angiotensin system or heart rate, offering an alternative mechanism for patients who need additional control or cannot tolerate other classes.

Moxonidin Actavis tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Moxonidin Actavis is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious adverse events include severe hypotension, bradycardia, and rare allergic reactions such as rash or swelling. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, or difficulty breathing.

Moxonidin Actavis is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the tablet. Caution is also advised for individuals with severe renal impairment, uncontrolled heart failure, or those taking other central antihypertensive agents without medical supervision.